Ons Marsit: What Is the Residual Thromboembolic Risk After AF Ablation?
Ons Marsit, Field Clinical Specialist at Boston Scientific, shared a post on LinkedIn about a recent article by Xiaodong Peng et al., published in EP Europace, adding:
”What is the residual thromboembolic risk after AF ablation?
A new EP Europace study used a target trial emulation to evaluate OAC discontinuation vs continuation in 8,339 patients after AF ablation.
Patients had CHA₂DS₂-VA greater than or equal to 2, no prior thromboembolism, and no documented atrial arrhythmia recurrence during the first 6 months after ablation.
Main findings
- No significant difference in the composite of stroke/systemic embolism and major bleeding: HR 0.93 (95 percent CI 0.67–1.29)
- No significant difference in thromboembolic events: HR 0.96 (95 percent CI 0.69–1.35)
- Clinically relevant non-major bleeding was lower after OAC discontinuation: HR 0.68 (95 percent CI 0.47–0.97)
Residual thromboembolic risk after OAC discontinuation according to CHA₂DS₂-VA:
- Score 2 to 0.64percent/year
- Score 3 to 0.86 percent/year
- Score greater than or equal to 4 to 1.52percent/year
The study highlights the importance of residual thromboembolic risk stratification after AF ablation, even among patients without documented recurrence during the first 6 months.
Rhythm surveillance was based on periodic Holter monitoring and symptom-driven ECG rather than continuous monitoring, so asymptomatic recurrences may have been missed.”
Title:Residual thromboembolic risk and outcomes of oral anticoagulation discontinuation after atrial fibrillation ablation: a target trial emulation
Authors: Xiaodong Peng, Liu He, Jue Wang, Sitong Li, Qifan Li, Zixu Zhao, Zejun Yang, Mingxiao Li, Fadong Li, Xiaoxia Liu, Song Zuo, Xueyuan Guo, Junmeng Zhang, Ning Zhou, Yunlong Wang, Deyong Long, Caihua Sang, Xin Du, Jianzeng Dong, Changsheng Ma
Stay updated with Hemostasis Today.
-
Nov 20, 2026, 17:27Adam Bryant: Great Science, Valuable Connections and a Wonderful Haematology Community at Blood 2026
-
Nov 20, 2026, 17:25Gurpreet Kaurr: Scientific Discussions, New Perspectives and Inspiration at HAEMATOCON 2026
-
Nov 20, 2026, 17:24Bispecific FVIIIa-Mimetic Antibodies in Haemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Nov 20, 2026, 17:23Khalid Rehman: Psychosocial Burden Among Caregivers of Patients with Beta-Thalassemia Major in Pakistan
-
Nov 20, 2026, 17:20Dhinesh Selvaraju: Caplacizumab Becomes the First FDA-Approved Treatment for Pediatric aTTP
-
Nov 20, 2026, 17:19Paris Margaritis: Presenting Preclinical Data on GENV-HEM at the WFH Workshop
-
Nov 20, 2026, 17:18WFH Opens Public Comment on Draft Guidelines for Hemostatic Agents and Prophylaxis
-
Nov 20, 2026, 17:18Ketan Asawale: Consensus on the Management of Cancer-Associated Thrombosis in India
-
Nov 20, 2026, 17:16Ajay Samkaria: The Evolution of Hemostasis Diagnostics with the ACL TOP 70 Series